Tony S.K. Mok, MD, on NSCLC: Review of Recent Data From the SUNRISE and ORIENT-31 Trials

ESMO Congress 2022


Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses two late-breaking abstracts presented at ESMO 2022: the phase II SUNRISE study, which compared sintilimab plus anlotinib vs platinum-based chemotherapy as first-line therapy in patients with metastatic non–small cell lung cancer (NSCLC); and the ORIENT-31 trial, which compared sintilimab with or without IBI305 (a bevacizumab biosimilar) plus chemotherapy in patients with EGFR-mutated nonsquamous NSCLC who experienced disease progression on EGFR tyrosine kinase inhibitors.


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
There are two abstracts from ESMO 2022 in Paris that I would like to share with you. The first one is ORIENT-31. This is actually a three-arm study. The first arm is sintilimab, which is an anti-PDL1 therapy together with a bevacizumab biosimilar with chemotherapy as arm A, arm B is actually chemotherapy with sintilimab only, and the third arm is the chemotherapy. Arm A and arm C comparison was previously reported, being positive and with a significant hazard ratio of 0.46. This time, at ESMO 2022, they reported the difference between arm B and arm C. They actually had an improvement of the median progression-free survival, about 5.5 months in the study arm and about 4.3 in the control arm. Hazard ratio is 0.72, statistically significant. But the question to me is how significant is significant? Well, first of all, EGFR mutation positive lung cancer patients, they actually don't have a good tumor microenvironment, so the single agent immunotherapy response rate on patients with EGFR mutation is actually about 10 to 12%. The combination may add onto the value, but then the question is, would it be the better approach or should we use another approach? So to that, there are data on the combination of the antiangiogenesis, but bevacizumab together with immunotherapy and also the use of the anti-PDL1 therapy. This one does actually have biological senses because VGF potentially can change the tumor microenvironment. So under that there are data from IMpower150, which is a subgroup analysis, not large, but then the four drug regimen is definitely better than the chemo with the bevacizumab alone. And also from the ORIENT study, the degree of improvement, the response rate, is 40%, which is actually higher. In my understanding, although sintilimab plus the chemotherapy is a positive study, but I don't think it's ready for clinical application. I will certainly wait for future randomized study, including Checkmate 722, which is chemo nivolumab versus chemo in EGFR-positive patients who failed the TKI, and also the KEYNOTE-789, which is the patient with, again, failed TKI randomized to chemo plus pembrolizumab versus chemotherapy. Until then, I actually would not just use routinely chemo plus IO, but then as a [inaudible 00:02:51], I may still consider the use of IMpower150. That is the first abstract on patients with EGFR mutation positive disease, how we may apply immunotherapy. Then the second abstract is called SUNRISE. This one is actually adding anlotinib, which is an oral VEGFR inhibitor to sintilimab, which is an anti-PDL1. The question is that a combination of antiangiogenesis and chemotherapy in patient without a driver mutation. This is a relatively small, randomized phase II study, about 98 patients were enrolled, the primary end point of response rate, looking at the control arm of chemotherapy at 25% versus the fact that the combination will be at 50%. Let's ask the question, is this the right study to do? Although the outcome is positive, they reported response rate of sintilimab plus anlotinib to be 50%, which had reached their primary goal. But then, the control arm is wrong. This study started in 2019. At that time we already divided patient into PDL1 over 50%, 1% to 49%, and less than 1%. Patient with over 50% of PDL1 expression, the control arm would be single agent IO, not chemotherapy. Patient with the PDL1, 1% to 49%, the control arm should be chemo plus IO and not chemotherapy alone. In this particular study, although as a group, they tend to show that there is a response rate of 50%, but then there's no meaning compared to a control arm that's no longer relevant anymore. In a sense, I'm afraid that this study does not add on any information to my daily practice.

Related Videos

Pancreatic Cancer

Christelle de la Fouchardiere, MD, on Pancreatic Ductal Adenocarcinoma: Phase III Trial Results With Gemcitabine Plus Paclitaxel

Christelle de la Fouchardiere, MD, of France’s Centre Léon Bérard, discusses phase III findings from the PRODIGE 65–UCGI 36–GEMPAX UNICANCER study, which evaluated whether the combination of gemcitabine and paclitaxel improves overall survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma after FOLFIRINOX failure or intolerance (Abstract LBA60).

Skin Cancer

Georgina V. Long, MD, PhD, on Melanoma: Findings on Circulating Tumor DNA, Disease Recurrence, and Immunotherapy

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, discusses results from the CheckMate 915 trial, an analysis of the pretreatment circulating tumor DNA, along with other clinical and translational baseline factors, and their association with disease recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy (Abstract 788O).

Colorectal Cancer

Marinde J.G. Bond, PhD Candidate, on Colorectal Liver Metastases: FOLFOX/FOLFIRI, Bevacizumab, and Panitumumab

Marinde J.G. Bond, PhD Candidate, of the University Medical Center, Utrecht, discusses phase III findings from the CAIRO5 study of the Dutch Colorectal Cancer Group, the first such trial in defined subgroups of patients with initially unresectable colorectal cancer liver metastases and left-sided and RAS/BRAF V600E wild-type tumor. The study compared FOLFOX/FOLFIRI plus either bevacizumab or panitumumab (Abstract LBA21).


Gynecologic Cancers

Paul A. DiSilvestro, MD, on Ovarian Cancer: New Data on Olaparib in Newly Diagnosed Disease

Paul A. DiSilvestro, MD, of Women & Infants Hospital and the Warren Alpert Medical School of Brown University, discusses overall survival results after a 7-year follow-up of the SOLO1/GOG-3004 trial for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib. Dr. DiSilvestro details the increasing role of such PARP inhibitors in ovarian cancer treatment and their benefit to patients (Abstract 517O).

Hepatobiliary Cancer

Richard S. Finn, MD, on Hepatocellular Carcinoma: Recent Data on Lenvatinib Plus Pembrolizumab

Richard S. Finn, MD, of the Geffen School of Medicine at the University of California, Los Angeles, discusses primary phase III results from the LEAP-002 study of pembrolizumab, an anti–PD-1 therapy, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor, vs lenvatinib monotherapy in patients with advanced hepatocellular carcinoma (Abstract LBA34).